Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare
company and leading manufacturer of plasma-derived medicines, today
announced it has completed the sale of a 20% equity stake in
Shanghai RAAS (SRAAS) to Haier Group Corporation (Haier Group) and
forged a strategic alliance with Haier Group. The deal has received
all necessary regulatory approvals and compliance confirmation from
the Shenzhen Stock Exchange.
The alliance will leverage synergies between
Grifols’ industry-leading plasma and diagnostic excellence and
Haier Group’s preeminent portfolio of healthcare solutions to
innovate and contribute to SRAAS’ growth in the long run.
Through a share purchase agreement Grifols has
sold a 20% equity stake in SRAAS to Haier Group for RMB 12.5
billion (approximately EUR 1.6 billion) cash consideration. Grifols
retains a significant 6.58% economic stake in SRAAS as well as a
seat on its Board of Directors.
The two companies extend their exclusive albumin
distribution agreement through the next 10 years – with guaranteed
minimum volumes between 2024 and 2028 – and SRAAS has the option to
prolong it through 2044. China’s demand for albumin is significant
and the demand is expected to grow significantly in the coming
years.
Grifols and SRAAS have collaborated successfully
over the last four years as the Chinese hemoderivatives market has
continued its booming double-digit growth.
With this transaction, first announced in
December 2023, Grifols maintains its presence in China and its
commercial agreements with SRAAS while it will comply with its
commitment to deleverage.
“We are delighted to close the transaction and
welcome Shanghai RAAS to the Haier healthcare family today.
Shanghai RAAS will join forces with Haier’s other healthcare
companies, including Haier Biomedical and Inkon Life, to expand our
footprint across life sciences, clinical medicine, and
biotechnology and build a globally competitive health ecosystem. We
also hope to contribute further to ‘Healthy China’ through our
strategic partnership with Grifols,” said Lixia Tan, Vice
Chairwoman and Executive Vice President of Haier
Group.
“The strategic alliance that we have forged with
Haier is a milestone in the more than 40-year history that Grifols
has in China and further positions us for growth in this
extraordinary market for plasma medicines and diagnostic solutions.
We look forward to working with Haier as we leverage our respective
capabilities to explore future business opportunities,” said
Thomas Glanzmann, Grifols Executive Chairman.
Grifols retained Osborne Clarke, S.L.P. and
JunHe LLP. as legal advisors. Nomura Securities International, Inc.
serves as the lead financial advisor to Grifols.
INVESTORS:
Grifols Investors Relations &
Sustainabilityinversores@grifols.com -
investors@grifols.comsostenibilidad@grifols.com
- sustainability@grifols.comTel. +34 93 571 02 21
MEDIA CONTACT:
Grifols Press Officemedia@grifols.comTel.: +34
93 571 00 02
SpainDuomo ComunicationTel.: +34 91 311 92 89 –
+34 91 311 92 90Raquel Lumbreras (Tel. +34 659 572
185)Raquel_lumbreras@duomocomunicacion.com Borja Gómez (Tel. +34
650 402 225)Borja_gomez@duomocomunicacion.com
Haier Press
Officeincaiermedia@haier.comHaiermedia@brunswickgroup.com
About Haier GroupFounded in
1984, Haier Group is a leading global provider of better life and
digital transformation solutions, inspired by the purpose “More
Creation, More Possibilities.” With users always at the center of
its businesses, Haier has built 10 R&D centers, 71 research
institutes, 35 industrial parks, 143 manufacturing centers and a
sales network of 230,000 nodes around the world. Haier is the
world's only IoT Ecosystem Brand that has been ranked in the Kantar
BrandZ Top 100 Most Valuable Global Brands for six consecutive
years. For more information about Haier Group, visit
www.haier.com
About Grifols
Grifols is a global healthcare company founded
in Barcelona in 1909 committed to improving the health and
well-being of people around the world. A leader in essential
plasma-derived medicines and transfusion medicine, the company
develops, produces, and provides innovative healthcare services and
solutions in more than 110 countries.
Patient needs and Grifols’ ever-growing
knowledge of many chronic, rare and prevalent conditions, at times
life-threatening, drive the company’s innovation in both plasma and
other biopharmaceuticals to enhance quality of life. Grifols is
focused on treating conditions across a broad range of therapeutic
areas: immunology, hepatology and intensive care, pulmonology,
hematology, neurology, and infectious diseases.
A pioneer in the plasma industry, Grifols
continues to grow its network of donation centers, the world’s
largest with over 390 across North America, Europe, Africa and the
Middle East, and China.
As a recognized leader in transfusion medicine,
Grifols offers a comprehensive portfolio of solutions designed to
enhance safety from donation to transfusion, in addition to
clinical diagnostic technologies. It provides high-quality
biological supplies for life-science research, clinical trials, and
for manufacturing pharmaceutical and diagnostic products. The
company also supplies tools, information and services that enable
hospitals, pharmacies and healthcare professionals to efficiently
deliver expert medical care.
Grifols, with more than 23,000 employees in more
than 30 countries and regions, is committed to a sustainable
business model that sets the standard for continuous innovation,
quality, safety, and ethical leadership.
The company’s class A shares are listed on the
Spanish Stock Exchange, where they are part of the Ibex-35
(MCE:GRF). Grifols non-voting class B shares are listed on the
Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs
(NASDAQ:GRFS).
For more information about Grifols, please visit
www.grifols.com
LEGAL DISCLAIMER
The facts and figures contained in this report
that do not refer to historical data are “future projections and
assumptions”. Words and expressions such as “believe”, “hope”,
“anticipate”, “predict”, “expect”, “intend”, “should”, “will seek
to achieve”, “it is estimated”, “future” and similar expressions,
in so far as they relate to the Grifols group, are used to identify
future projections and assumptions. These expressions reflect the
assumptions, hypotheses, expectations and predictions of the
management team at the time of writing this report, and these are
subject to a number of factors that mean that the actual results
may be materially different. The future results of the Grifols
group could be affected by events relating to its own activities,
such as a shortage of supplies of raw materials for the manufacture
of its products, the appearance of competitor products on the
market, or changes to the regulatory framework of the markets in
which it operates, among others. At the date of compiling this
report, the Grifols group has adopted the necessary measures to
mitigate the potential impact of these events. Grifols, S.A. does
not accept any obligation to publicly report, revise or update
future projections or assumptions to adapt them to events or
circumstances subsequent to the date of writing this report, except
where expressly required by the applicable legislation. This
document does not constitute an offer or invitation to buy or
subscribe shares in accordance with the provisions of the following
Spanish legislation: Royal Legislative Decree 4/2015, of 23
October, approving recast text of Securities Market Law; Royal
Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4
November, and any regulations developing this legislation. In
addition, this document does not constitute an offer of purchase,
sale or exchange, or a request for an offer of purchase, sale or
exchange of securities, or a request for any vote or approval in
any other jurisdiction. The information included in this document
has not been verified nor reviewed by the external auditors of the
Grifols group.
Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Sep 2024 to Oct 2024
Eagle Capital Growth (AMEX:GRF)
Historical Stock Chart
From Oct 2023 to Oct 2024